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Purpose: To investigate the clinical effects of a single high dose intravenous immu-
noglobulin (IVIG) combined with initial dexamethasone as a primary treatment on 
Kawasaki disease (KD). Materials and Methods: Between January 2008 and De-
cember 2010, we reviewed the medical records of 216 patients with complete KD 
patients that were admitted to a single medical center. 106 patients were treated with 
a single high dose of IVIG (2 g/kg) alone and 110 patients received IVIG and dexa-
methasone (0.3 mg/kg per day for three days). Results: The combined IVIG plus 
dexamethasone patient group had a significantly shorter febrile period and duration 
of hospital stay (1.4±0.7 days vs. 2.0±1.2 days, p<0.001; 5.8±1.7 days vs. 6.9±2.5 
days, p<0.001, respectively) than the IVIG alone group. The combined IVIG plus 
dexamethasone group required IVIG retreatment significantly less than the IVIG 
only group (12.7% vs. 32%, p=0.003). After completion of the initial IVIG, C-reac-
tive protein levels in the combined IVIG plus dexamethasone group were signifi-
cantly lower than those in the IVIG only group (2.7±4.0 mg/dL vs. 4.6±8.7 mg/dL, 
p=0.03). In the combined IVIG plus dexamethasone group, the incidence of coro-
nary artery lesions tended to be lower without worse outcomes at admission after ini-
tial infusion of IVIG and in follow-up at two months; however, the differences were 
not significant (8.2% vs. 11.3%, p=0.22; 0.9% vs. 2.8%, p=0.29). Conclusion: Ini-
tial combined therapy with dexamethasone and a single high-dose of IVIG resulted 
in an improved clinical course, in particular a shorter febrile period, less IVIG re-
treatment, and shorter hospital stay without worse coronary outcomes.
Key Words:   Dexamethasone, high-dose intravenous immunoglobulin, combined 
therapy, Kawasaki disease
INTRODUCTION
Kawasaki disease (KD) is a form of acute vasculitis that occurs during childhood 
with clinical features of fever, rash, oral mucositis, conjunctival injection, change 
of extremities and cervical lymphadenopathy. As a serious complication in Kawa-
saki disease, coronary aneurymal alteration leads to acquired coronary heart dis-
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rash; and cervical lymphadenopathy.1 The duration of fever 
was significantly related to increased risk and progression 
of CAL. Exclusion criteria included a previous diagnosis of 
KD, presence of a previous CAL, incomplete KD with 
fewer than four features of KD, and initial consultation af-
ter a febrile duration longer than 10 days, as these condi-
tions may have an effect on clinical results and CAL out-
comes. This study was approved by the Institutional 
Review Board of Ajou University Hospital.
Treatment protocols
One hundred and ten patients out of 216 patients were treat-
ed intravenously with 0.3 mg/kg of dexamethasone per day 
(0.1 mg/kg, 3 times a day) for three consecutive days, begin-
ning on the same day as the initial IVIG infusion (2 g/kg) as 
a primary treatment of acute KD, and comprised the com-
bined IVIG plus dexamethasone (IVIG+DEX) group. The 
0.3 mg/kg per day dose of dexamethasone used in this study 
has equivalent anti-inflammatory potency to 2 mg/kg per 
day of prednisolone used in a previous study.9,10 Additionally, 
oral acetylsalicylic acid (80 mg/kg per day) was started to-
gether with IVIG and dexamethasone. A group of 106 con-
trol KD patients received standard therapy with a single high-
dose infusion of IVIG (2 g/kg) only plus oral aspirin (80 mg/
kg per day). Non-responsiveness to initial therapy is defined 
as persistent or recrudescent fever longer than 48 hours af-
ter completion of the initial IVIG infusion. Non-responsive 
patients received an additional IVIG (1 g/kg/dose, 1--2 dos-
es) with oral aspirin. Laboratory investigations were per-
formed at admission before treatment and at 1 week after 
initial IVIG infusion, as well as at 2 weeks and 2 months 
later in two groups. CAL was defined when the luminal di-
ameter exceeded 3.0 mm in a child under the age of 5 years 
or 4.0 mm in a child aged 5 years or older, when the inter-
nal diameter of a segment was at least 1.5 times that of an 
adjacent segment, or when the luminal contour was clearly 
irregular.1 A two-dimensional echocardiogram was con-
ducted 2 days after completion of the initial IVIG therapy 
and again at 2 weeks and 2 months thereafter. The exami-
nation of the adverse effects of dexamethasone in the IVIG 
plus DEX group were examined with blood pressure and 
an echocardiogram for the analysis of thrombosis or ectasia 
in the coronary arteries.
Statistical analysis
The results are presented as mean±standard deviation. For 
comparison of the two groups, the numeric values were an-
ease in children. Coronary artery lesions (CAL) develop in 
approximately 15% to 25% of untreated cases and standard 
therapy with intravenous immunoglobulin (IVIG) has been 
reported to be effective in reducing the incidence of CAL in 
KD patients.1 However, 11% to 23% of KD patients still 
have a persistent fever or recurrent fever after completion 
of IVIG.2 These patients, who are non-responsive to the ini-
tial treatment regimen, are recommended a retreatment 
with IVIG and additional regimens, such as methylprednis-
olone pulse therapy, infliximab and cyclophosphamide.1,3-6 
Since Kato, et al.6 reported that corticosteroids increase 
the risk of CAL, corticosteroid therapy for treatment of KD 
has been limited. Recently, steroid therapy with pulsed 
methylprednisolone was introduced to children whose fever 
is not alleviated despite more than two infusions of IVIG in 
refractory KD. Corticosteroids reduce fever and prevent the 
progression of coronary artery complications as a result of 
KD and suggest the possibility of a steroid regimen com-
bined with IVIG as an initial therapy in KD.7-9 Dexametha-
sone with long-acting anti-inflammatory activity is more po-
tent than methylprednisolone and is clinically used in pulsed 
steroid therapy. In a previous study, it improved pre-extuba-
tion pulmonary edema and cerebral vasogenic edema in 
brain tumor and meningitis.10 In vitro, it experimentally in-
hibits three relevant cell-types, monocytes, T lymphocytes, 
and human coronary arterial endothelial cells, all of which 
play a role in vasculitis and tissue edema, along with coro-
nary complications, observed in KD patients.11 We studied 
the clinical effects of high-dose IVIG combined with initial 
dexamethasone as a primary treatment for KD.
MATERIALS AND METHODS
Subjects
From January 2008 to December 2010, we enrolled patients 
at Ajou University Hospital. We retrospectively reviewed 
the medical records and laboratory data of KD patients. KD 
was diagnosed according to the criteria as defined by the 
American Heart Association. All patients exhibited at least 
five of the following features: fever lasting longer than 5 
days (axillary or ear temperature exceeding 38.0°C); non-
exudative conjunctival injection; changes in the orophar-
ynx, including mucosal erythema, dry cracked red lips, and 
strawberry tongue; changes in the extremities, including 
palmar and plantar erythema, edema of the hands and feet, 
and periungual desquamation; generalized polymorphorous 
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0.001 by the t-test). The mean duration of hospital stay in 
the IVIG plus DEX group was also significantly shorter than 
that in the IVIG only group (5.8±1.7 days vs. 6.9±2.5 days, 
mean±SD; p<0.001). The mean total dosage of IVIG on ad-
mission in the IVIG plus DEX group was remarkably lower 
than that in the IVIG only group (2.1±0.3 g/kg vs. 2.4±0.5 g/
kg, mean±SD; p<0.001). Non-responsive rate to the initial 
therapy was 22.2% (48/216) for the entire patient popula-
tion; 14 patients were in the IVIG plus DEX group and 34 
patients belonged to the IVIG only group. The percentage of 
non-responsive patients was lower in the IVIG+DEX group 
than that in the IVIG only group (12.7% vs. 32%; p=0.003 
by the chi-squared test). Patients in the IVIG plus DEX group 
showed more rapid clinical improvement and required less 
immunoglobulin treatment. Some patients after initial ther-
apy were readmitted for recurrent fever and other features 
consistent with KD. The rate of readmission in the IVIG plus 
DEX group was lower than that in the IVIG only group; 
however, the difference was not significant (5.4% vs. 10.4%; 
p=0.12 by the chi-squared test) (Table 2).
On the serial echocardiograms after treatment, the inci-
dence of CAL in the IVIG plus DEX group was less fre-
quent than the control group 2 days after completion of ini-
tial IVIG therapy, at two weeks, and at two months (8.2% 
vs. 11.3%, p=0.22; 4.5% vs. 7.5%, p=0.26; 0.9% vs. 2.8%, 
p=0.29) (Table 3). These differences were not significant 
between the two groups. Most findings regarding CAL im-
proved at two months after the initial treatment, and persis-
tent CAL was infrequent as it was observed in only 4 patients 
(4/216, 1.9%) in our study. There was no giant coronary an-
eurysm defined as an internal diameter >8 mm. CAL of one 
patient in the IVIG plus DEX group presented with a dila-
tation of the left coronary artery (diameter 6 mm). Three 
patients in the IVIG only group had a medium to large 
alyzed using the independent samples t-test for unpaired val-
ues. Categorical data were assessed by the chi-squared test. 
A p value <0.05 was considered statistically significant. The 
statistical analyses were conducted using the SPSS statistical 
package, version 12.0 (SPSS Inc., Chicago, IL, USA). 
 
RESULTS
 
Patient population 
The demographic and laboratory data for both the experi-
mental and control groups before treatment are summarized 
in Table 1. There were no significant differences in age 
(30.6±20.2 months vs. 29.9±20.5 months, mean±standard 
deviation; p=0.97 by the t-test), sex distribution (boy/girl, 
67/39 vs. 72/39; p=0.54 by the chi-squared test) and febrile 
duration on admission (5.4±1.7 days vs. 5.3±1.0 days, 
mean±SD; p=0.95 by the t-test) between the control IVIG 
only group and the IVIG plus DEX groups. The groups 
were well balanced with respect to demographic and clini-
cal characteristics. The laboratory data of the two groups on 
admission were not significantly different with regards to 
white blood cell counts, hematocrit, platelet counts, albu-
min, erythrocyte sedimentation rate, and C-reactive protein 
(Table 1). All patients were monitored for at least two 
months (range, 2 to 38 months). No serious adverse effects 
such as hypertension or thromboses were reported in any of 
the KD patients, including those in the IVIG plus DEX 
group. 
Clinical outcomes
The average febrile duration after the initial treatment in the 
IVIG plus DEX group was significantly shorter than that in 
the IVIG only group (1.7±0.7 vs. 2.0±1.2, mean±SD; p< 
Table 1. Demographic and Laboratory Comparison of the Two Groups before Treatment (n=216) 
IVIG only (n=106) IVIG+DEX (n=110) p value 
Age (months)   30.6±20.2   29.9±20.5 0.97 
Sex (boy/girl) 67/39 71/39 0.54 
Febrile duration (days)   5.4±1.7   5.3±1.0 0.95 
White blood cell (×103/uL) 13.5±4.8 13.6±3.9 0.14 
Hematocrit (%) 33.2±2.7 33.4±2.7 0.47 
Platelet (×103/uL)   358±135 335±92 0.21 
Albumin (g/dL)   3.9±0.4   3.9±0.3 0.24 
ESR (mm/hr)   51.4±23.9   60.3±25.0 0.46 
C-reactive protein (mg/dL)   7.7±5.5   7.8±5.4 0.68 
IVIG, intravenous immunoglobulin; DEX, dexamethasone; ESR, erythrocyte sedimentation rate.
Mean±SD, independent t-test and chi-squared test, p<0.05. 
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13.8 ×103/uL vs. 517±14.8 ×103/uL, mean±SE; p<0.001, 
322±6.9 ×103/uL vs. 361±8.5 ×103/uL, mean±SE; p<0.001) 
(Fig. 1B). At two months, the mean erythrocyte sedimenta-
tion rate (ESR) in the IVIG plus DEX group also decreased 
significantly, compared to the IVIG only group (6.7±0.7 mm/
hr, vs. 9.6±1.2 mm/hr, mean±SE; p=0.04) (Fig. 1C). Also, in 
non-responsive patients, platelet counts at 2 months in the 
IVIG plus DEX groups were significantly lower than those 
in the IVIG only group (316±81 ×103/uL vs. 369±80 ×103/
uL, mean±SD; p=0.04). ESR in the IVIG plus DEX group 
was also lower significantly than that in the IVIG only group 
(5.0±3.7 mm/hr vs. 11.6±1.4 mm/hr, mean±SD; p=0.02) for 
non-responsive patients.
DISCUSSION
Standard therapy with IVIG and aspirin for the treatment of 
KD has significantly reduced the incidence of coronary ar-
tery abnormalities since Furusho, et al.12 reported the benefi-
cial effects of high-dose IVIG treatment for KD. Nonethe-
less, when a high-dose of IVIG is administered, approxima-
tely 5% of children with KD experience transient coronary 
artery dilatation and 1% of them develop large aneurysms. 
Approximately 15% of KD patients exhibit persistent or re-
current fever after IVIG completion, which puts then at an 
increased risk of CAL.13-15 Recent studies have recommend-
ed novel treatments for non-responsive patients including 
repeated doses of IVIG, intravenous pulse methylpredniso-
lone, plasma exchange, ulinastatin, abciximab, infliximab, 
sized dilatation of the right and left coronary arteries (each 
diameter 4.3 mm, 5 mm, 7 mm). CAL in two patients with 
diameters of 4.3 mm and 5 mm, regressed within 18 months 
of illness. The absolute number of CAL’s reported for the 
IVIG plus DEX group was less than that reported in the 
control group. An annual echocardiogram was conducted 
for patients with large aneurysms without development of 
CAL. None of the patients had adverse effects with regards 
to thrombosis in the coronary artery on echocardiogram. 
For the non-responsive cases, the incidence of CAL was 
not different between the two groups, however, each group 
had only a small number of cases, 1 case in the IVIG plus 
DEX group and 2 cases in the IVIG only group.
Laboratory data for the IVIG plus DEX group and the 
IVIG only group
After completion of the initial IVIG treatment, the average 
level of C-reactive protein (CRP) in the IVIG plus DEX 
group was significantly lower than that in the IVIG only 
group (2.7±0.04 mg/dL vs. 4.6±0.06 mg/dL, mean±standard 
error; p=0.03). The magnitude of decrease in the CRP levels 
in the IVIG plus DEX group was larger than that in the IVIG 
only group at 1 week after completion of the initial IVIG. 
Both of the mean CRP levels decreased to the same level as 
the normal range observed at two months (Fig. 1A). The seri-
al platelet count in the IVIG plus DEX group was elevated 
early and decreased to levels lower than those obtained for 
the IVIG only group. The platelet counts at two weeks and 
two months were decreased significantly more in the IVIG 
plus DEX group than those in the IVIG only group (435± 
Table 2. Comparison of Clinical Outcomes after Treatment (n=216) 
IVIG only (n=106) IVIG+DEX (n=110) p value 
Febrile duration after treatment (day) 2.0±1.2 1.7±0.7   <0.001* 
Hospitalized duration (day) 6.9±2.5 5.8±1.7   <0.001* 
IVIG total dosage (g/kg) 2.4±0.5 2.1±0.3   <0.001* 
Non-responsive cases (No.%) 34/106 (32.0) 14/110 (12.7)   <0.003*
Readmission (No. %) 11/106 (10.4) 6/110 (5.4) 0.12 
IVIG, intravenous immunoglobulin; DEX, dexamethasone.
Mean±SD, independent t-test and chi-squared test. 
*p<0.01. 
Table 3. The Incidence of Coronary Artery Lesions
Time IVIG only (n=106) IVIG+DEX (n=110) p value 
After initial IVIG therapy (%) 12 (11.3) 9 (8.2) 0.22
At 2 wks (%)  8 (7.5) 5 (4.5) 0.26
At 2 months (%) 3 (2.8) 1 (0.9) 0.29
IVIG, intravenous immunoglobulin; DEX, dexamethasone.
Incidence %, chi-squared test, p<0.05.
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including Dr. Kawasaki. Before the first report of IVIG effi-
cacy in KD, corticosteroid therapy was used as the initial 
treatment for KD. There were several reports regarding the 
use of corticosteroids in KD due to its potential to amelio-
rate blood vessel damage by suppressing inflammatory ef-
fectors that lead to endothelial cell injury and weakening of 
the vessel wall.18,19 Nevertheless, in the pre-IVIG era, many 
clinicians thought that steroid therapy might be harmful, as 
steroid might cause coronary thrombosis and aneurismal 
change in KD. An early study by Kato, et al.6 suggested a 
high incidence of coronary artery aneurysms in KD patients 
treated with prednisolone alone (11 of 17 patients), and as a 
result, steroids were thought to be harmful. In the post-
IVIG era, corticosteroid therapy was used with or after the 
additional IVIG regimen as a rescue therapy in refractory 
KD. The pulsed steroid therapy in KD patients who pre-
sented with recrudescent fever was associated with an im-
provement of fever and CAL progression. In the study by 
Dahlem, et al.20 pulsed intravenous methylprednisolone was 
effective in relieving persistent fever and large pericardial 
effusions unresponsive to multiple treatments with IVIG. 
Additionally, Dale, et al.21 reported that oral prednisolone (2 
mg/kg/day, for 14 days) and aspirin were effective for se-
vere complications in KD patients treated with initial IVIG 
therapy (2 g/kg). Previously, Hashino, et al.5 demonstrated 
the efficacy and safety of additional pulsed steroid therapy 
after multiple IVIG infusions in shortening febrile duration 
and lowering medical costs. As well, Wright, et al.3 report-
ed the effectiveness of intravenous pulse methylpredniso-
lone as a rescue therapy for non-responsive KD patients in 
comparison to standard IVIG therapy. The results from re-
cent research have led to recommendations of an additional 
steroid regimen of intravenous pulse methylprednisolone 
(30 mg/kg/day, for 3 days) for KD patients, as additional 
infusions with IVIG have proven ineffective in relieving 
persistent fever and acute inflammation.3,5 
The steroid treatment combined with IVIG was intro-
duced recently as a primary therapy for KD. Shinohara, et 
al.22 reported that a regimen of prednisolone and immuno-
globulin (200--400 mg/kg/d for 5 days) with aspirin is asso-
ciated with shorter febrile duration and a decreased inci-
dence of CAL when used as a primary therapy for acute 
KD. Sundel, et al.9 suggested that the initial methylprednis-
olone therapy with IVIG as a primary therapy in KD led to 
faster resolution of fever, rapid improvement in inflamma-
tory markers, and shorter length of hospitalization. Labora-
tory measurements, such as serum CRP, and clinical mark-
and cyclosphamide.1,16,17 However, the effectiveness and 
adverse potentially adverse effects of several of these treat-
ment options are uncertain due to the limited number of 
participants in the studies. 
Corticosteroids are a strong anti-inflammatory agent used 
for the treatment of vasculitis, and have been mentioned to 
be of potential use in treatment of KD by many clinicians 
Fig. 1. Changes in laboratory findings between the IVIG only group and IVIG 
plus dexamethasone group (DEX+IVIG): (A) for mean C-reactive protein 
(CRP), (B) for mean platelet count, and (C) for mean erythrocyte sedimenta-
tion rate (ESR). *p<0.05, IVIG only group vs. DEX+IVIG group. DEX, dexa-
methasone; IVIG, intravenous immunoglobulin.
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combination of dexamethasone and a single high-dose infu-
sion of IVIG (2 g/kg) demonstrated a more favorable clinical 
course with decreased febrile duration and length of hospi-
tal stay. The combined dexamethasone therapy decreased 
the need for additional IVIG treatments and lowered non-
responsive rates to initial treatment. These results were sup-
ported by serial results of clinical inflammatory markers, 
such as CRP and ESR. The levels for both CRP and ESR 
decreased more sharply and normalized faster in the combi-
nation therapy group than the IVIG only group. In regards to 
coronary outcomes, CALs were not worse in the combined 
therapy group than the IVIG only group. Our results on cor-
onary outcomes are in direct contrast to the pre-IVIG era re-
ports of increased risks of coronary aneurysm in KD pa-
tients treated with corticosteroid.
Our study had a few limitations including small number of 
patients in the combined dexamethasone and IVIG group 
that did not show better coronary outcomes. Recent trends 
regarding treatment choices for patients that do not respond 
to IVIG treatment for KD have included additional infusions 
of one or two more doses of IVIG, secondary pulsed steroid 
therapy with intravenous methylprednisolone 30 mg/kg/day 
for three days, and finally treatment with a tumor necrotizing 
factor-α blocker, such as infliximab. However, the therapeu-
tic superiority thereof has been not been proven.30 Although 
the number of cases was very small, there were fewer non-
responsive cases in the combined dexamethasone therapy 
than in the IVIG only group. Nevertheless, our results sug-
gest combined dexamethasone therapy may decrease fever 
sooner and require less additional therapy such as infliximab 
whose effects on refractory KD still remain uncertain. As 
another limitation of our study, the levels of selected cyto-
kines were not analyzed in relation to the combined steroid 
therapy in KD. We suggest that levels of inflammatory cyto-
kines could support the efficacy of the combined steroid 
therapy. Further studies with a large number of patients will 
be required to definitively demonstrate the effectiveness of 
combined dexamethasone as an initial therapy in KD. 
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